NCT03920228View on ClinicalTrials.gov

Phase 2/3 Study Evaluating the Safety and Efficacy of PTX-022 in Treatment of Adults With Pachyonychia Congenita

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

September 19, 2020

Study Completion Date

October 19, 2020

Conditions
Pachyonychia Congenita
Interventions
DRUG

PTX-022

PTX-022 QTORIN

DRUG

Placebo

Placebo topical

Trial Locations (9)

19103

Paddington Testing Co., Philadelphia

33144

International Dermatology Research, Miami

55432

Minnesota Clinical Study Center, Fridley

60611

Northwestern University, Chicago

84107

University of Utah, Murray

85053

Arizona Research Center, Phoenix

94304

Stanford University, Palo Alto

97239

Oregon Health and Science University, Portland

06519

Yale University, New Haven

Sponsors
All Listed Sponsors
lead

Palvella Therapeutics, Inc.

INDUSTRY